Annual Congress: Hematologic Malignancies

2024 NCCN Hem Congress

Registration Open!

2024 Annual Congress: Hematologic Malignancies™ 
Friday, September 20 – Saturday, September 21, 2024
New York Marriott Marquis • New York, New York | Virtual attendance also available

Annual Congress: Hematologic Malignancies New York City Location

Register by Aug. 5 for the best rates!
Learn More
Join us in New York!
Learn More
Designed for the entire oncology team!
View Agenda

Annual Congress: Hematologic Malignancies Panels

Continuing Education

Chaired by Andrew D. Zelenetz, MD, PhD, from Memorial Sloan Kettering Cancer Center, this program features presentations and interactive discussions highlighting the treatment options and supportive care for a variety of hematologic malignancies. This program is approved for AMA PRA Category 1 Credit™ and ABIM, ABPath, and ABMS MOC for physicians and is certified for credit for PAs, nurses, pharmacists, and other oncology professionals.


Topics and disease areas to be covered:

  • Acute Lymphocytic Leukemia (ALL)
  • Acute Myeloid Leukemia (AML)
  • Amyloidosis
  • Bispecific Antibodies
  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
  • CAR T-Cell Therapies 
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
  • Chronic Myeloid Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Myelodysplastic Syndromes (MDS)
  • Myelofibrosis
  • Primary CNS Lymphoma

For CE program supporter opportunities, contact Lisa Perfidio, Senior Manager, CE Supporter Outreach.

Exhibition Hall

View Exhibitor Propsectus


For exhibitor opportunities, contact

Important Alert About Fraudulent Sites

Information about this Congress may appear on fraudulent websites that appear to offer registration, exhibit space, and hotel rooms at discounted rates. These companies are in no way affiliated with NCCN. Please do not book any registrations or reservations through these sites, and register only through NCCN. If you have any questions or concerns, contact